Spatiotemporally programming cytokine immunotherapies through protein engineering

Area of Science:

• Immunology
• Oncology
• Protein Engineering

Background:

• Cytokines like Interleukin-2 (IL-2) and Interferon-ɑ (IFNɑ) show promise in cancer immunotherapy but have limited clinical success.
• Early cytokine therapies faced challenges due to narrow therapeutic windows and dose-limiting toxicities from systemic administration.
• The localized, regulated endogenous cytokine action contrasts with the systemic, untargeted delivery of exogenous therapies.

Purpose of the Study:

• To explore protein engineering strategies for improving cytokine-based cancer immunotherapies.
• To address the limitations of first-generation cytokine therapies through advanced protein design.
• To contextualize cytokine engineering through spatiotemporal regulation for enhanced therapeutic potential.

Main Methods:

• Review and contextualization of protein engineering strategies for cytokines.
• Focus on strategies like partial agonism, conditional activation, and intratumoral retention.
• Analysis through the lens of spatiotemporal regulation of cytokine signaling.

Main Results:

• Protein engineering offers solutions to overcome narrow therapeutic windows and dose-limiting toxicities.
• Strategies like partial agonism and conditional activation enable controlled cytokine signaling.
• Intratumoral retention improves localized delivery and therapeutic effect.

Conclusions:

• Protein engineering can enable exogenous cytokine therapies to more closely mimic endogenous profiles.
• Controlling the time, place, specificity, and duration of cytokine signaling is key.
• These advancements bring us closer to unlocking the full therapeutic potential of cytokines in cancer treatment.